Clinical Trial: Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine W

Brief Summary: This is a study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals live attenuated measles-mumps-rubella-varicella vaccine given to healthy children in their second year of life.

Detailed Summary:
Sponsor: GlaxoSmithKline

Current Primary Outcome: Antibody levels after vaccination.

Original Primary Outcome: Same as current

Current Secondary Outcome: Safety of the study vaccines.

Original Secondary Outcome: Same as current

Information By: GlaxoSmithKline

Dates:
Date Received: August 4, 2005
Date Started: May 2005
Date Completion:
Last Updated: September 20, 2016
Last Verified: September 2016